- Holzer, R.A., Persons, R.K. and Jamieson, B., 2011. Evaluation of ovarian cysts.
OvaCis® is a globally patented Point-Of-Care device that accurately discriminates benign from malignant epithelial Ovarian Cancer in 15 minutes.
”As many as 1 in 10 women is likely to have an ovarian cyst in their lifetime
An ovarian cyst happens when fluid accumulates within a thin membrane inside the ovary. Ovarian cysts are frequently found incidentally in asymptomatic women and may sometimes be found in the course of evaluating women for pelvic pain.
5%-10% women with ovarian cysts will have surgery, of which 13%-21% of women that undergo intra-operative evaluation are found to have cancer. During the intra-operative evaluation, a procedure called Frozen Section is performed by slicing and preparing a section of freeze-dried ovarian tissue for microscopic examination. However, this procedure is not universally available, takes up to 60 minutes, with low accuracy.
OvaCis®, an intra-operative point of care’s medical device to determine if the ovarian cyst is benign or malignant within 15 minutes.
ADVANTAGES OVER FROZEN SECTION
Diagnosis for ovarian cancer has routinely been performed via frozen section, which is subject to technical error, leading to misdiagnosis. In comparison, OvaCis® relies on cyst fluid which is homogenous, resulting in higher accuracy.
COST EFFICIENT AND CONVENIENT TO USE
OvaCis® is ideal for medical settings with no on-site facilities for histology, and costs less than frozen section. It does not require trained pathologists, substantially reduces operating theatre time, and frees up resources in the laboratory.
BETTER PATIENT PROGNOSIS
OvaCis® reduces operating theatre time and the patient’s surgical exposure in the operating theatre. It is the first of its kind Point-Of-Care device that returns a result in about 5 minutes, improving patient’s prognosis during surgery.